Inhibikase Therapeutics Enhances Leadership with Timothy Pigot's Appointment as Chief Commercial and Strategy Officer

Company Overview: Inhibikase Therapeutics is a biotechnology company focused on developing treatments for neurodegenerative diseases.

Recent Developments: The company has received a "Buy" rating from analysts, indicating positive expectations for its future performance.

Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.

Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.

Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.

Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.

New Appointment: Inhibikase Therapeutics has appointed Timothy Pigot as Chief Commercial and Strategy Officer, bringing extensive experience in the pharmaceutical industry, particularly in pulmonary arterial hypertension (PAH).

Leadership Insight: CEO Mark Iwicki expressed confidence in Pigot's expertise and connections within the PAH market, which will be crucial as the company advances its lead product candidate, IKT-001, towards late-stage clinical trials.

Company Background: Inhibikase Therapeutics focuses on developing therapies for cardiopulmonary diseases, specifically targeting PAH, a serious condition affecting around 50,000 Americans.

Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future activities and potential risks that could impact their progress and results.

Company Developments: Inhibikase Therapeutics is advancing its lead product candidate, IKT-001, towards a Phase 2b clinical trial for Pulmonary Arterial Hypertension (PAH), with study initiation expected in the second half of 2025. The trial will evaluate different dosages of IKT-001 compared to placebo in approximately 150 participants.

Financial Overview: For the quarter ending June 30, 2025, Inhibikase reported a net loss of $9.9 million and cash reserves of $87.7 million, reflecting an increase in research and development expenses due to the acquisition of CorHepta and ongoing clinical trials.

Company Developments: Inhibikase Therapeutics reported a net loss of $13.7 million for Q1 2025 and is preparing to initiate a Phase 2b clinical study of IKT-001 for pulmonary arterial hypertension (PAH) in the second half of 2025, with a strengthened leadership team in place.

Financial Overview: The company's research and development expenses surged to $10.5 million due to an acquisition, while cash reserves stood at $93.2 million as of March 31, 2025, reflecting ongoing investments in their PAH treatment initiatives.

Investigation Announcement: Purcell & Lefkowitz LLP is investigating Inhibikase Therapeutics, Inc. to determine if its directors breached fiduciary duties related to recent corporate actions.

Shareholder Support: Shareholders of Inhibikase Therapeutics can seek additional information about their rights and options through the law firm, which specializes in representing victims of securities fraud and corporate misconduct.